Olema Pharmaceuticals inc (OLMA)
11.24
+0.34
(+3.17%)
USD |
NASDAQ |
May 07, 16:00
11.24
0.00 (0.00%)
After-Hours: 20:00
Olema Pharmaceuticals Enterprise Value: 347.66M for May 6, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 06, 2024 | 347.66M |
| May 03, 2024 | 334.80M |
| May 02, 2024 | 301.25M |
| May 01, 2024 | 319.71M |
| April 30, 2024 | 306.85M |
| April 29, 2024 | 306.29M |
| April 26, 2024 | 294.54M |
| April 25, 2024 | 287.83M |
| April 24, 2024 | 305.73M |
| April 23, 2024 | 297.34M |
| April 22, 2024 | 290.07M |
| April 19, 2024 | 293.43M |
| April 18, 2024 | 291.75M |
| April 17, 2024 | 337.04M |
| April 16, 2024 | 343.19M |
| April 15, 2024 | 344.87M |
| April 12, 2024 | 345.43M |
| April 11, 2024 | 384.01M |
| April 10, 2024 | 349.90M |
| April 09, 2024 | 382.89M |
| April 08, 2024 | 368.35M |
| April 05, 2024 | 336.48M |
| April 04, 2024 | 325.86M |
| April 03, 2024 | 357.73M |
| April 02, 2024 | 344.31M |
| Date | Value |
|---|---|
| April 01, 2024 | 347.10M |
| March 28, 2024 | 371.15M |
| March 27, 2024 | 364.44M |
| March 26, 2024 | 350.46M |
| March 25, 2024 | 351.58M |
| March 22, 2024 | 366.12M |
| March 21, 2024 | 384.01M |
| March 20, 2024 | 388.48M |
| March 19, 2024 | 384.01M |
| March 18, 2024 | 357.73M |
| March 15, 2024 | 384.01M |
| March 14, 2024 | 385.13M |
| March 13, 2024 | 437.13M |
| March 12, 2024 | 417.00M |
| March 11, 2024 | 465.08M |
| March 08, 2024 | 465.08M |
| March 07, 2024 | 524.91M |
| March 06, 2024 | 525.14M |
| March 05, 2024 | 498.74M |
| March 04, 2024 | 538.89M |
| March 01, 2024 | 552.09M |
| February 29, 2024 | 420.10M |
| February 28, 2024 | 451.45M |
| February 27, 2024 | 492.69M |
| February 26, 2024 | 482.25M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-185.55M
Minimum
May 11 2022
2.061B
Maximum
Dec 01 2020
375.18M
Average
240.29M
Median
Aug 29 2023
Enterprise Value Benchmarks
| Geron Corp | 1.852B |
| Verastem Inc | 202.60M |
| Fate Therapeutics Inc | 103.61M |
| Karyopharm Therapeutics Inc | 111.80M |
| Alpine Immune Sciences Inc | 3.908B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.77M |
| Total Expenses (Quarterly) | 30.42M |
| EPS Diluted (Quarterly) | -0.48 |
| Earnings Yield | -19.12% |